For your adult patients with persistent or chronic ITP who failed their first therapy …
How Do Your Treatment Considerations
Fit Within the Guidelines ?
2019 ASH guidelines 1 :
X Guidelines suggest the need to limit steroid use to ≤6 weeks with tapering
X For patients who value a durable response ,* ASH guidelines suggest a TPO-RA in 2L
X Route of administration may determine the selection of TPO-RA
Patient portrayal .
2L , second line ; ASH , American Society of Hematology ; ITP , immune thrombocytopenia ; TPO-RA , thrombopoietin receptor agonist . * The 2019 ASH guidelines define durable response as a platelet count ≥30,000 / mcL and at least doubling of the baseline count at 6 months . 1
Indication and Important Safety Information
Indication for PROMACTA ® ( eltrombopag ) PROMACTA is indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia ( ITP ) who have had an insufficient response to corticosteroids , immunoglobulins , or splenectomy . PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding .
Limitations of Use PROMACTA is not indicated for the treatment of patients with myelodysplastic syndromes ( MDS ).
Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection .
Important Safety Information for PROMACTA ® ( eltrombopag )
WARNING : RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C In patients with chronic hepatitis C , PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation .
RISK OF HEPATOTOXICITY PROMACTA may increase the risk of severe and potentially life-threatening hepatotoxicity . Monitor hepatic function and discontinue dosing as recommended .
Please see additional Important Safety Information for PROMACTA and Brief Summary of full Prescribing Information , including Boxed WARNING , on adjacent pages .
This paid advertisement was developed by Novartis , the manufacturer of PROMACTA , independently of ASH Clinical News and the American Society of Hematology ( ASH ). The information contained herein does not constitute endorsement by the publication or ASH .